Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations
| Authors | |
|---|---|
| Year of publication | 2022 |
| Type | Article in Periodical |
| Magazine / Source | HemaSphere |
| MU Faculty or unit | |
| Citation | |
| Web | https://journals.lww.com/hemasphere/Fulltext/2022/04000/Cytogenetics_in_Chronic_Lymphocytic_Leukemia__ERIC.6.aspx |
| Doi | http://dx.doi.org/10.1097/HS9.0000000000000707 |
| Keywords | Chronic Lymphocytic Leukemia; Cytogenetics |
| Description | Mounting evidence underscores the clinical value of cytogenetic analysis in chronic lymphocytic leukemia (CLL), particularly as it allows the identification of complex karyotype, that has recently emerged as a prognostic and potentially predictive biomarker. That said, explicit recommendations regarding the methodology and clinical interpretation of either chromosome banding analysis (CBA) or chromosome microarray analysis (CMA) are still lacking. We herein present the consensus of the Cytogenetic Steering Scientific Committee of ERIC, the European Research Initiative on CLL, regarding methodological issues as well as clinical interpretation of CBA/CMA and discuss their relevance in CLL. ERIC considers CBA standardized and feasible for CLL on the condition that standards are met, extending from the use of novel mitogens to the accurate interpretation of the findings. On the other hand, CMA, is also standardized, however, robust data on its clinical utility are still scarce. In conclusion, cytogenetic analysis is not yet mature enough to guide treatment choices in CLL. That notwithstanding, ERIC encourages the wide application of CBA, and potentially also CMA, in clinical trials in order to obtain robust evidence regarding the predictive value of specific cytogenetic profiles towards refining risk stratification and improving the management of patients with CLL. |
| Related projects: |
|